JP5560472B2 - インフルエンザウイルス感染症の治療剤 - Google Patents
インフルエンザウイルス感染症の治療剤 Download PDFInfo
- Publication number
- JP5560472B2 JP5560472B2 JP2011535462A JP2011535462A JP5560472B2 JP 5560472 B2 JP5560472 B2 JP 5560472B2 JP 2011535462 A JP2011535462 A JP 2011535462A JP 2011535462 A JP2011535462 A JP 2011535462A JP 5560472 B2 JP5560472 B2 JP 5560472B2
- Authority
- JP
- Japan
- Prior art keywords
- test
- influenza virus
- group
- aureobasidium
- test group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims description 61
- 230000009385 viral infection Effects 0.000 title claims description 44
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 94
- 241000894006 Bacteria Species 0.000 claims description 53
- 235000014655 lactic acid Nutrition 0.000 claims description 47
- 239000004310 lactic acid Substances 0.000 claims description 47
- 229920002498 Beta-glucan Polymers 0.000 claims description 35
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 29
- 241000223678 Aureobasidium pullulans Species 0.000 claims description 24
- 206010022000 influenza Diseases 0.000 claims description 23
- 241000194032 Enterococcus faecalis Species 0.000 claims description 18
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 239000003443 antiviral agent Substances 0.000 claims description 9
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 239000002911 sialidase inhibitor Substances 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 59
- 241000223651 Aureobasidium Species 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 51
- 241000699666 Mus <mouse, genus> Species 0.000 description 42
- 208000015181 infectious disease Diseases 0.000 description 41
- 230000037396 body weight Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 28
- 229960003752 oseltamivir Drugs 0.000 description 28
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 28
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 24
- 239000002953 phosphate buffered saline Substances 0.000 description 24
- 241000700605 Viruses Species 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 210000000822 natural killer cell Anatomy 0.000 description 20
- 230000004580 weight loss Effects 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 206010049040 Weight fluctuation Diseases 0.000 description 15
- 239000012085 test solution Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 description 13
- 229940061367 tamiflu Drugs 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 8
- 241000879125 Aureobasidium sp. Species 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 229940017800 lactobacillus casei Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000186012 Bifidobacterium breve Species 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 229920001218 Pullulan Polymers 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000019423 pullulan Nutrition 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 229920000310 Alpha glucan Polymers 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940124393 anti-influenza virus drug Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 229960001028 zanamivir Drugs 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- NTJHUKMPVIFDNY-XFDPNJHTSA-N (6r,7r)-7-[[(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[1,2-b]pyridazin-4-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound [Cl-].N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 NTJHUKMPVIFDNY-XFDPNJHTSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LUXIJPQYUCFVAL-XRLCNELCSA-N 2,2-dimethylpropanoyloxymethyl (6r,7r)-7-[[(z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydron;chloride;hydrate Chemical compound O.Cl.N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 LUXIJPQYUCFVAL-XRLCNELCSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241000197306 H1N1 subtype Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229950004627 cefcapene pivoxil Drugs 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- -1 cefditrepivoxil Chemical compound 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002676 cefmetazole sodium Drugs 0.000 description 1
- BWRRTAXZCKVRON-DGPOFWGLSA-N cefotiam dihydrochloride Chemical compound Cl.Cl.CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 BWRRTAXZCKVRON-DGPOFWGLSA-N 0.000 description 1
- 229960004700 cefotiam hydrochloride Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000798 isepamicin Drugs 0.000 description 1
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940061374 relenza Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0208—Specific bacteria not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
[1] アウレオバシジウム属(Aureobasidium sp.)に属する微生物の培養物から得られるβ−グルカン含有組成物を有効成分として含有し、インフルエンザウイルス感染症の重症化を抑制し、治癒を促進するために用いられるものであることを特徴とするインフルエンザウイルス感染症の治療剤。
[2] 前記アウレオバシジウム属(Aureobasidium sp.)に属する微生物は、アウレオバシジウム プルランスM−1(Aureobasidium pullulans M-1)(FERM BP-08615)又はアウレオバシジウム プルランスM−2(Aureobasidium pullulans M-2)(FERM BP-10014)である上記[1]記載のインフルエンザウイルス感染症の治療剤。
[3] 更に、乳酸菌の菌体を有効成分として含有する上記[1]又は[2]記載のインフルエンザウイルス感染症の治療剤。
[4] 前記乳酸菌の菌体がエンテロコッカス・フェカリス(Enterococcus faecalis)の死菌体である上記[3]記載のインフルエンザウイルス感染症の治療剤。
[5] インフルエンザノイラミニダーゼ阻害剤、抗ウイルス剤、抗生物質、及びステロイド剤からなる群から選ばれた少なくとも1種と組み合わせて投与されることを特徴とする上記[1]〜[4]のいずれか1つに記載のインフルエンザウイルス感染症の治療剤。
数式1:β−グルカン(g/100g)=ブドウ糖(g/100g)×0.9
下記のようにしてアウレオバシジウム プルランスM−1(Aureobasidium pullulans M-1)(FERM BP-08615)の培養液を調製した。
下記表1に記載の各試験群及び対照群についてそれぞれ試験液を準備し、これらの経口投与がインフルエンザウイルスを感染させたマウスに対してどのような効果を示すかを調べた。なお、抗インフルエンザ薬であるオセルタミビルとしては、「タミフルドライシロップ3%」(商品名、中外製薬株式会社)を利用した。
製造例1と同様にして、アウレオバシジウム プルランスM−2(Aureobasidium pullulans M-2)(FERM BP-10014)の培養液を調製した。その培養液は、固形分およそ1.2質量%を含み、該固形分100g中のβ?グルカン含量は54.2gであった。また、培養液そのものの質量100g中に含まれる含有量に換算して、0.65g/100g含有するものであった。この培養液を以下の試験に用いた。
下記表3に記載のように、各試験群及び対照群についてそれぞれ試験液を準備し、これらの経口投与がインフルエンザウイルスを感染させたマウスに対してどのような効果を示すかを調べた。なお、表中のEF乳酸菌死菌体は、市販のエンテロコッカス・フェカリス(Enterococcus faecalis)の加熱殺菌菌体粉末である。
乳酸菌の菌体との併用による効果を更に検討した。具体的には、下記表5に示す各試験群及び対照群について、それぞれ試験液を準備し、試験例2と同様にして、これらを経口投与するとともにインフルエンザウイルスを感染させたマウスの体重の推移と生存率を調べた。なお、表中のEF乳酸菌死菌体は、市販のエンテロコッカス・フェカリス(Enterococcus faecalis)の加熱殺菌菌体粉末である。
試験例1〜試験例3で示された効果の作用機序を検討するために、インフルエンザウイルスに感染させたマウスの肺中のウイルス力価に与える影響を調べた。具体的には、下記表7に示す各試験群及び対照群について、それぞれ試験液を準備し、これらを経口投与するとともにインフルエンザウイルスを感染させたマウスの肺中のウイルス力価を調べた。なお、表中のEF乳酸菌死菌体は、市販のエンテロコッカス・フェカリス(Enterococcus
faecalis)の加熱殺菌菌体粉末である。
試験例1〜試験例3で示された効果の作用機序を検討するために、インフルエンザウイルスに感染させたマウスの肺中の活性化T細胞及び活性化NK細胞を調べた。具体的には、下記表10に示す各試験群及び対照群について、それぞれ試験液を準備し、これらを経口投与するとともにインフルエンザウイルスを感染させたマウスの5日目の肺中のT細胞数とそのうちの活性化T細胞、またNK細胞数とそのうちの活性化NK細胞を調べた。なお、表中のEF乳酸菌死菌体は、市販のエンテロコッカス・フェカリス(Enterococcus faecalis)の加熱殺菌菌体粉末である。
Claims (5)
- アウレオバシジウム プルランスに属する微生物の培養物から得られるβ−グルカン含有組成物を有効成分として含有し、インフルエンザウイルス感染症の重症化を抑制し、治癒を促進するために用いられるものであることを特徴とするインフルエンザウイルス感染症の治療剤。
- 前記アウレオバシジウム プルランスに属する微生物は、アウレオバシジウム プルランスM−1(Aureobasidium pullulans M-1)(FERM BP-08615)又はアウレオバシジウム プルランスM−2(Aureobasidium pullulans M-2)(FERM BP-10014)である請求項1記載のインフルエンザウイルス感染症の治療剤。
- 更に、乳酸菌の菌体を有効成分として含有する請求項1又は2記載のインフルエンザウイルス感染症の治療剤。
- 前記乳酸菌の菌体がエンテロコッカス・フェカリス(Enterococcus faecalis)の死菌体である請求項3記載のインフルエンザウイルス感染症の治療剤。
- インフルエンザノイラミニダーゼ阻害剤、抗ウイルス剤、抗生物質、及びステロイド剤からなる群から選ばれた少なくとも1種と組み合わせて投与されることを特徴とする請求項1〜4のいずれか1つに記載のインフルエンザウイルス感染症の治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011535462A JP5560472B2 (ja) | 2009-10-08 | 2010-10-07 | インフルエンザウイルス感染症の治療剤 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009234023 | 2009-10-08 | ||
JP2009234023 | 2009-10-08 | ||
JP2009265049 | 2009-11-20 | ||
JP2009265049 | 2009-11-20 | ||
JP2011535462A JP5560472B2 (ja) | 2009-10-08 | 2010-10-07 | インフルエンザウイルス感染症の治療剤 |
PCT/JP2010/067680 WO2011043435A1 (ja) | 2009-10-08 | 2010-10-07 | インフルエンザウイルス感染症の治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2011043435A1 JPWO2011043435A1 (ja) | 2013-03-04 |
JP5560472B2 true JP5560472B2 (ja) | 2014-07-30 |
Family
ID=43856885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011535462A Active JP5560472B2 (ja) | 2009-10-08 | 2010-10-07 | インフルエンザウイルス感染症の治療剤 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20120202771A1 (ja) |
EP (1) | EP2486931B1 (ja) |
JP (1) | JP5560472B2 (ja) |
TW (1) | TWI496578B (ja) |
WO (1) | WO2011043435A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021049587A1 (ja) | 2019-09-11 | 2021-03-18 | 株式会社アウレオ | 抗体医薬の効果増強用組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9896706B2 (en) | 2012-07-17 | 2018-02-20 | Shigenobu Miura | Method for producing β-glucan |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002204687A (ja) * | 2000-11-09 | 2002-07-23 | Onaka Yasushi | β−1.3−1.6グルカン(アウレオバシジウム培養液)の医療、保健、福祉、食品および各種産業分野での応用 |
JP2003523401A (ja) * | 2000-02-23 | 2003-08-05 | バイオテク ファーマコン エイエスエイ | 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方 |
JP2005220065A (ja) * | 2004-02-05 | 2005-08-18 | Aureo Co Ltd | 免疫賦活剤 |
JP2005281227A (ja) * | 2004-03-30 | 2005-10-13 | Masanobu Ouchi | インフルエンザウイルス感染症の治療および予防薬 |
JP2006075076A (ja) * | 2004-09-09 | 2006-03-23 | Aureo Co Ltd | β−グルカン含有組成物、その製造方法及び該組成物を含む飲食品若しくは皮膚用保湿剤 |
JP2006104439A (ja) * | 2004-03-29 | 2006-04-20 | Daiso Co Ltd | β−1,3−1,6−D−グルカンおよびその用途 |
JP2008013543A (ja) * | 2006-06-07 | 2008-01-24 | Daiichi Sankyo Healthcare Co Ltd | 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物 |
WO2008053728A1 (fr) * | 2006-11-02 | 2008-05-08 | Aureo Co., Ltd. | Agent favorisant la guérison d'un organisme vivant |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57149301A (en) | 1981-03-11 | 1982-09-14 | Daiichi Togyo Kk | Novel polysaccharide having coagulating property |
US6956120B2 (en) * | 2000-11-09 | 2005-10-18 | Yasushi Onaka | β-1.3-1.6 glucan (Aureobasidium medium) |
ATE519490T1 (de) * | 2003-03-07 | 2011-08-15 | Aureo Co Ltd | Zusammensetzung mit beta-glucan und obstipationslinderndes mittel, immunopotentiator und hautbefeuchtungsmittel unter verwendung der zusammensetzung |
US7981930B2 (en) * | 2007-03-13 | 2011-07-19 | Adamas Pharmaceuticals, Inc. | Compositions and kits for treating influenza |
JP2008308438A (ja) * | 2007-06-14 | 2008-12-25 | Mitsubishi Tanabe Pharma Corp | 新規なインフルエンザ治療および/または予防薬 |
CN101802191A (zh) * | 2007-07-03 | 2010-08-11 | 杏林制药株式会社 | 流感治疗 |
-
2010
- 2010-10-06 TW TW099133967A patent/TWI496578B/zh active
- 2010-10-07 WO PCT/JP2010/067680 patent/WO2011043435A1/ja active Application Filing
- 2010-10-07 JP JP2011535462A patent/JP5560472B2/ja active Active
- 2010-10-07 US US13/499,941 patent/US20120202771A1/en not_active Abandoned
- 2010-10-07 EP EP10822105.2A patent/EP2486931B1/en active Active
-
2014
- 2014-03-28 US US14/229,636 patent/US20140199346A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523401A (ja) * | 2000-02-23 | 2003-08-05 | バイオテク ファーマコン エイエスエイ | 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方 |
JP2002204687A (ja) * | 2000-11-09 | 2002-07-23 | Onaka Yasushi | β−1.3−1.6グルカン(アウレオバシジウム培養液)の医療、保健、福祉、食品および各種産業分野での応用 |
JP2005220065A (ja) * | 2004-02-05 | 2005-08-18 | Aureo Co Ltd | 免疫賦活剤 |
JP2006104439A (ja) * | 2004-03-29 | 2006-04-20 | Daiso Co Ltd | β−1,3−1,6−D−グルカンおよびその用途 |
JP2005281227A (ja) * | 2004-03-30 | 2005-10-13 | Masanobu Ouchi | インフルエンザウイルス感染症の治療および予防薬 |
JP2006075076A (ja) * | 2004-09-09 | 2006-03-23 | Aureo Co Ltd | β−グルカン含有組成物、その製造方法及び該組成物を含む飲食品若しくは皮膚用保湿剤 |
JP2008013543A (ja) * | 2006-06-07 | 2008-01-24 | Daiichi Sankyo Healthcare Co Ltd | 有胞子性乳酸菌含有抗感冒ウイルス又は抗インフルエンザウイルス用組成物 |
WO2008053728A1 (fr) * | 2006-11-02 | 2008-05-08 | Aureo Co., Ltd. | Agent favorisant la guérison d'un organisme vivant |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021049587A1 (ja) | 2019-09-11 | 2021-03-18 | 株式会社アウレオ | 抗体医薬の効果増強用組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2486931A1 (en) | 2012-08-15 |
US20120202771A1 (en) | 2012-08-09 |
TWI496578B (zh) | 2015-08-21 |
US20140199346A1 (en) | 2014-07-17 |
EP2486931B1 (en) | 2014-05-14 |
JPWO2011043435A1 (ja) | 2013-03-04 |
WO2011043435A1 (ja) | 2011-04-14 |
EP2486931A4 (en) | 2013-04-10 |
TW201119661A (en) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10124016B2 (en) | Immune system stimulating nutrition | |
US20120141541A1 (en) | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages | |
US20050272694A1 (en) | Composition containing beta-glucan and constipation-relieving drug, immunopotentiatior, and skin moistening agent using the composition | |
CN112370470A (zh) | 一种重建肠道微生态的微生态制剂 | |
JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
CN110392734A (zh) | 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌 | |
KR20190141707A (ko) | 복용 미생물군 촉진 조성물 및 그 사용방법 | |
JP4369258B2 (ja) | 免疫賦活剤 | |
CN112402459A (zh) | 普拉梭菌缓解过敏性哮喘和鼻炎Th2反应中的应用 | |
TW201100084A (en) | Compositions comprising oligosaccharides | |
WO2004084912A1 (ja) | 神経障害処置剤 | |
JP5560472B2 (ja) | インフルエンザウイルス感染症の治療剤 | |
EP3574910A1 (en) | Mrsa infection protective agent | |
JP4054697B2 (ja) | 便秘改善剤 | |
KR101833249B1 (ko) | 상피세포간 접착 증강제 및 이것을 이용한 알러지 질환의 개선, 치료 또는 예방제 | |
JPH03246296A (ja) | 新規糖アルコール | |
TWI230611B (en) | Anti-infection composition and food containing such anti-infection composition | |
JP2007508233A (ja) | 抗ウイルス剤 | |
EP4353245A1 (en) | Composition for preventing or treating inflammatory diseases or cancer, comprising leuconostoc bacteria-derived vesicles | |
WO2023120547A1 (ja) | 二次性感染症の予防又は発症リスクを低減するための組成物 | |
JP3013064B2 (ja) | 乳酸菌生育促進剤 | |
JPH0338593A (ja) | 新規オリゴ糖とその製造法及び利用 | |
CN114431484A (zh) | 人乳寡糖在提高肠道对沙门氏菌感染抵御能力中的应用 | |
TW202233209A (zh) | 中草藥多醣及其細菌組成物改善疾病的用途 | |
CN116731218A (zh) | 一种菌菇多糖提取物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140120 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140513 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5560472 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |